Coverage would include diagnostic testing to determine appropriate treatments, as well as prescribed treatments or ...

Alzheimer’s disease, the most common form of dementia, affects millions of people worldwide, slowly robbing them of their ...

A decade ago, researchers introduced a new model for studying Alzheimer's disease. Known as "Alzheimer's in a dish," the model uses cultures of mature brain cells suspended in a gel to recapitulate ...

A recent study from the University of California, San Diego, has found a troubling link between certain commonly used ...

A potential new treatment for Alzheimer’s disease may come in the form of a nasal spray. Researchers in Italy have discovered ...

A local man from Detroit was among the first patients in the country to receive a newly-approved drug that can treat early onset Alzheimer's Disease.

Thanksgiving travel is a must for millions of Americans, but those plans will be complicated for some because they’re ...

BridgeBio’s Attruby wins approval for transthyretin amyloid cardiomyopathy while the FDA accepts Alnylam’s application for ...

Cassava Sciences' simufilam failed a Phase III trial for Alzheimer's disease, likely marking the end of a drug surrounded by ...

Andrew Fein, an analyst from H.C. Wainwright, maintained the Buy rating on Vigil Neuroscience Inc (VIGL – Research Report). The associated ...

Cassava Sciences' Alzheimer's drug simufilam failed key trial endpoints, leading to a stock plunge. See why SAVA stock is at risk of delisting or merger.